CAJ | 학술논문

目的：观察吉西他滨联合奥沙利铂方案（GEMOX 方案）治疗复发难治性非霍奇金淋巴瘤（NHL）的临床疗效和毒副反应。方法回顾性分析32例接受过GEMOX方案治疗的复发难治性NHL患者，每两周评价疗效，每周观察毒副反应。结果32例复发难治性NHL患者中，完全缓解（CR）9例，部分缓解（PR）13例，维持稳定（SD）6例，进展（PD）4例；客观有效率为（CR+PR）68.8％，临床获益率（CR+PR+SD）87.5％；中位无疾病进展时间（PFS）为8.5个月（1.5~12.5个月）；主要不良反应为骨髓抑制，无治疗相关性死亡。结论 GEMOX方案对复发或难治性NHL疗效确切，毒副反应耐受良好，是复发难治性NHL可选的挽救性化疗方案。
목적：관찰길서타빈연합오사리박방안（GEMOX 방안）치료복발난치성비곽기금림파류（NHL）적림상료효화독부반응。방법회고성분석32례접수과GEMOX방안치료적복발난치성NHL환자，매량주평개료효，매주관찰독부반응。결과32례복발난치성NHL환자중，완전완해（CR）9례，부분완해（PR）13례，유지은정（SD）6례，진전（PD）4례；객관유효솔위（CR+PR）68.8％，림상획익솔（CR+PR+SD）87.5％；중위무질병진전시간（PFS）위8.5개월（1.5~12.5개월）；주요불량반응위골수억제，무치료상관성사망。결론 GEMOX방안대복발혹난치성NHL료효학절，독부반응내수량호，시복발난치성NHL가선적만구성화료방안。
Objective The purpose of this study is to evaluate the efficacy and the toxicity of GEMOX regimen on relapsed or refractory non-Hodgkin’s lymphoma. Methods We analyzed 32 relapsed or relapsing non-Hodgkin’s Lymphoma patients, retrospectively. All patients received the treatment of GEMOX regimen (gemcitabine 1000 mg·m-2 on Day l and Day 8, oxaliplatin 130 mg·m-2 on Day 1) every three weeks for one cycle, and the efficacy and toxicity was evaluated after two consecutive cycles following RECIST criteria. Results Of all the patients, 9 cases had complete remission;13 had partial remission;6 were of stable disease and 4 were of progressive disease. The objective response rate (ORR) was 68.8%, and the disease control rate (DCR) was 87.5%. The median progress free survival (PFS) was 8.5 months (1.5~12.5 months). The main adverse toxicity was bone marrow suppression. There was no treatment-related death. Conclusion The GEMOX regimen has a definite efficacy and well-tolerance on relapsed or relapsing non-Hodgkin’s lymphoma. It was a rescuing option for relapsed or relapsing non-Hodgkin’s lymphoma.